academic article

• Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial..  The Lancet. Oncology.  13:100-110. 2012
• Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial..  The Lancet. Oncology.  13:89-99. 2012
• The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years..  The Journal of infectious diseases.  199:936-944. 2009
• Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial..  Lancet.  369:2161-2170. 2007
• Once-daily valacyclovir to reduce the risk of transmission of genital herpes..  The New England journal of medicine.  350:11-20. 2004